Bcl-xL is a dominant antiapoptotic protein that inhibits homoharringtonine-induced apoptosis in leukemia cells

Molecular Pharmacology

Volumn 79, Issue 6, 2011, Pages 1072-1083

  Yin, Shiliang ^a   Wang, Rui ^c   Zhou, Fan ^b   Zhang, Hong ^a   Jing, Yongkui ^c  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; HOMOHARRINGTONINE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN HL 60; CELL STRAIN K 562; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN FUNCTION;

APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; HARRINGTONINES; HUMANS; LEUKEMIA; RNA INTERFERENCE;

EID: 79956300440     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.068528     Document Type: Article

References (39)

1. Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, and Green DR (1998) Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene 16:1383-1390. (Pubitemid 28151845)
2. Boyd AW and Sullivan JR (1984) Leukemic cell differentiation in vivo and in vitro: arrest of proliferation parallels the differentiation induced by the antileukemic drug Harringtonine. Blood 63:384-392. (Pubitemid 14188887)
3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
4. Chen D, Chan R, Waxman S, and Jing Y (2006) Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors. Cancer Res 66:11416-11423. (Pubitemid 46009973)
5. de Groot RP, Raaijmakers JA, Lammers JW, and Koenderman L (2000) STAT5- dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun 3:299-305.
6. de Lavallade H, Khorashad JS, Davis HP, Milojkovic D, Kaeda JS, Goldman JM, Apperley JF, and Marin D (2007) Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood 110:2779-2780. (Pubitemid 47523217)
7. Deininger MW, Goldman JM, and Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343-3356.
8. Dubrez-Daloz L, Dupoux A, and Cartier J (2008) IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle 7:1036-1046.
9. Elrod HA and Sun SY (2008) Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther 7:163-173. (Pubitemid 351590418)
10. Emaus RK, Grunwald R, and Lemasters JJ (1986) Rhodamine 123 as a probe of transmembrane potential in isolated rat-liver mitochondria: spectral and metabolic properties. Biochim Biophys Acta 850:436-448. (Pubitemid 16077550)
11. Fresno M, Jiménez A, and Vázquez D (1977) Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem 72:323-330. (Pubitemid 8022231)
12. Grem JL, Cheson BD, King SA, Leyland-Jones B, and Suffness M (1988) Cephalotaxine esters: antileukemic advance or therapeutic failure? J Natl Cancer Inst 80:1095-1103.
13. Huang CC, Han CS, Yue XF, Shen CM, Wang SW, Wu FG, and Xu B (1983) Cytotoxicity and sister chromatid exchanges induced in vitro by six anticancer drugs developed in the People's Republic of China. J Natl Cancer Inst 71:841-847. (Pubitemid 14232400)
14. Huang MT (1975) Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharmacol 11:511-519.
15. Jie H, Donghua H, Xingkui X, Liang G, Wenjun W, Xiaoyan H, and Zhen C (2007) Homoharringtonine-induced apoptosis of MDS cell line MUTZ-1 cells is mediated by the endoplasmic reticulum stress pathway. Leuk Lymphoma 48:964-977. (Pubitemid 47161569)
16. Jin J, Jiang DZ, Mai WY, Meng HT, Qian WB, Tong HY, Huang J, Mao LP, Tong Y, Wang L, et al. (2006) Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia 20:1361-1367. (Pubitemid 44084048)
17. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, and Waxman S (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94:2102-2111. (Pubitemid 29430427)
18. Kuroda J, Kamitsuji Y, Kimura S, Ashihara E, Kawata E, Nakagawa Y, Takeuichi M, Murotani Y, Yokota A, Tanaka R, et al. (2008) Anti-myeloma effect of homo-harringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin. Int J Hematol 87:507-515.
19. Kuroda J and Taniwaki M (2009) Involvement of BH3-only proteins in hematologic malignancies. Crit Rev Oncol Hematol 71:89-101.
20. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, and Berger R (1991) NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77:1080-1086.
21. Leber B, Lin J, and Andrews DW (2010) Still embedded together binding to membranes regulates Bcl-2 protein interactions. Oncogene 29:5221-5230.
22. Lombard C, Nagarkatti M, and Nagarkatti PS (2005) Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. Leuk Res 29:915-922. (Pubitemid 40840719)
23. Lou YJ, Qian WB, and Jin J (2007) Homoharringtonine induces apoptosis and growth arrest in human myeloma cells. Leuk Lymphoma 48:1400-1406.
24. Marin D, Kaeda JS, Andreasson C, Saunders SM, Bua M, Olavarria E, Goldman JM, and Apperley JF (2005) Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 103:1850-1855.
25. O'Dwyer PJ, King SA, Hoth DF, Suffness M, and Leyland-Jones B (1986) Homoharringtonine-perspectives on an active new natural product. J Clin Oncol 4:1563-1568. (Pubitemid 17183582)
26. O'Hare T, Eide CA, and Deininger MW (2008) New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin Investig Drugs 17:865-878. (Pubitemid 351864324)
27. Ohmine K, Nagai T, Tarumoto T, Miyoshi T, Muroi K, Mano H, Komatsu N, Takaku F, and Ozawa K (2003) Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR. Stem Cells 21:315-321. (Pubitemid 36623173)
28. Pennati M, Folini M, and Zaffaroni N (2007) Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 28:1133-1139. (Pubitemid 47062670)
29. Quintás-Cardama A, Kantarjian H, and Cortes J (2009) Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 115:5382-5393.
30. Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, et al. (2007) Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109:248-255. (Pubitemid 46106239)
31. Rahmani M, Anderson A, Habibi JR, Crabtree TR, Mayo M, Harada H, Ferreira- Gonzalez A, Dent P, and Grant S (2009) The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood 114:4507-4516.
32. Stone RM, Donohue KA, Stock W, Hars V, Linker CA, Shea T, Deangelo DJ, Marcucci G, Bloomfield CD, Larson RA, et al. (2009) A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol 63:859-864.
33. Tang R, Faussat AM, Majdak P, Marzac C, Dubrulle S, Marjanovic Z, Legrand O, and Marie JP (2006) Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther 5:723-731.
34. Tujebajeva RM, Graifer DM, Karpova GG, and Ajtkhozhina NA (1989) Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation. FEBS Lett 257:254-256.
35. Visani G, Russo D, Ottaviani E, Tosi P, Damiani D, Michelutti A, Manfroi S, Baccarani M, and Tura S (1997) Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia 11:624-628.
36. Yokoyama A, Okabe-Kado J, Uehara Y, Oki T, Tomoyasu S, Tsuruoka N, and Honma Y (1996) Angelmicin B, a new inhibitor of oncogenic signal transduction, inhibits growth and induces myelomonocytic differentiation of human myeloid leukemia HL-60 cells. Leuk Res 20:491-497. (Pubitemid 26254538)
37. Yu Z, Wang R, Xu L, Dong J, and Jing Y (2008) N-(beta-Elemene-13-yl) tryptophan methyl ester induces apoptosis in human leukemia cells and synergizes with arsenic trioxide through a hydrogen peroxide dependent pathway. Cancer Lett 269:165-173.
38. Zhang WG, Wang FX, Chen YX, Cao XM, He AL, Liu J, Ma XR, Zhao WH, Liu SH, and Wang JL (2008) Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia. Am J Hematol 83:185-188. (Pubitemid 351303940)
39. Zhou JY, Chen DL, Shen ZS, and Koeffler HP (1990) Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro. Cancer Res 50:2031-2035.